TABLE 1.
Microorganisms and plasmids used in this study
| Strain or plasmid | Description or genotypea | Source or reference |
|---|---|---|
| Strains | ||
| E. coli DH5α | Φ80dlacZΔDM15 recA1 endA1 gyrA96 thi-1 hsdR17 (rK− mK+) supE44 relA1 deoR Δ(lacZYA-argF)U169 phoA | Invitrogen (Shanghai, China) |
| E. coli BL21 | ||
| Bacillus velezensis SQR9 | Wild type | CGMCC no. 5808 |
| B. velezensis SQR9-gfp | GFP-labeled SQR9 (Kanr) | |
| B. velezensis SQR9M6 | SQR9 Δsfp::cm | 60 |
| SQR9 ΔggaA | This study | |
| GFP-labeled SQR9 ΔggaA (Cmr) | This study | |
| SQR9 Δ3020 | This study | |
| GFP-labeled SQR9 Δ3020 (Cmr) | This study | |
| SQR9 ΔgtaB | This study | |
| GFP-labeled SQR9 ΔgtaB (Cmr) | This study | |
| Plasmids | ||
| pTPC | pMD19-T harboring the Pbc-pheS*-cat(PC) cassette | 54 |
| pNW33n | Cmr; MCS | BGSC |
| pNW33n-GFP | This study |
a
Kanr, kanamycin resistance; Cmr, chloramphenicol resistance; MCS, multiple-cloning site; Δ3020, mutant with deletion of V529_36590 (https://www.ncbi.nlm.nih.gov/protein/631803020).